Hormone therapy after endometrial cancer

Hormone Research

Volumn 62, Issue 1, 2004, Pages 40-48

  Mueck, Alfred O ^a   Seeger, Harald ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Endometrial cancer; Hormone therapy; Risk factors, hormone therapy

Indexed keywords

CLONIDINE; CONJUGATED ESTROGEN; GABAPENTIN; MEDROXYPROGESTERONE ACETATE; METHYLDOPA; PROPRANOLOL; RALOXIFENE; SEROTONIN UPTAKE INHIBITOR; TIBOLONE; TRANQUILIZER; TRICYCLIC ANTIDEPRESSANT AGENT; VERALIPRIDE;

BREAST CARCINOMA; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CONSTIPATION; DRUG ELIMINATION; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; GASTROINTESTINAL HEMORRHAGE; HOT FLUSH; HUMAN; NAUSEA; NEUROTOXICITY; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REVIEW; RISK FACTOR; SUICIDE; TREATMENT CONTRAINDICATION; WITHDRAWAL SYNDROME; XEROSTOMIA;

ENDOMETRIAL NEOPLASMS; FEMALE; HORMONES; HUMANS;

EID: 3142777812     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000078786     Document Type: Review

References (54)

1. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland: Krebs in Deutschland - Häufigkeiten und Trends, ed 3. Saarbrücken 2002.
2. Sturdee DW: Is 'HRT' the correct terminology. J Br Menopause Soc 2003;9:53.
3. American College of Obstetricians and Gynecologists Committee Opinion: Committee on Gynecologic Practice: Estrogen Replacement Therapy and Endometrial Cancer, No.126, 1993.
4. Creasman WT: HRT and women who have had breast or endometrial cancer. J Epidemiol Biostat 1999;4:217-225.
5. Mueck AO, Wallwiener D: Hormonsubstitution nach Brustkrebs. Med Welt 2003;54:51-56.
6. American Cancer Society: Cancer Facts and Figures. Atlanta, American Cancer Society, 2002.
7. Oehler MK, Brand A, Wain GV: Molecular genetics and endometrial cancer. J Br Menopause Soc 2003;9:27-31.
8. Kenemans P: Postmenopausal sex hormones and cancer of the endometrium and breast. J Br Menopause Soc 2000;6(Supp.3):4-9.
9. Römer T, Mueck AO: Endometrium und Hormonsubstitution. Stuttgart, Thieme, 1998, pp 47-54.
10. Mueck AO, Seeger H, Wallwiener D: Impact of hormone replacement therapy on endogenous estradiol metabolism in postmenopausal women. Maturitas 2002;43:87-93.
11. Mueck AO, Seeger H: Smoking, estradiol metabolism and hormone replacement therapy. Arzneimittelforschung 2003;53:1-11.
12. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-1037.
13. Bjarnason K, Cerin A, Lindgren R, Weber T: Adverse endometrial effects during long cycle hormone replacement therapy. Scandinavian Long Cycle Study Group. Maturitas 1999;32:161-170.
14. Erkkola R, Kumento U, Lehmuskoski S, Mattila L, Mustonen M: No increased risk of endometrial hyperplasia with fixed long-cycle hormone replacement therapy after two years. J Br Menopause Soc 2002;8:155-156.
15. Rabe T, Mueck AO, Deuringer FU, Runnebaum B: Spacing out of progestin - efficacy, tolerability and compliance of two regimens for hormonal replacement in the late postmenopause. Gynecol Endocrinol 1997;11:383-392.
16. Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergström R, Lindgren A, Correia N, Persson I: Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131-1137.
17. Hill DA, Weiss NS, Beresford SA, Voigt LF, Daling JR, Stanford JL, Self S: Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol 2000;183:1456-1461.
18. Sturdee DW, Ulrich LG, Barlow DH, Wells M, Campbell MJ, Vessey MP, Nielsen B, Anderson MC, Bragg AJ: The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy. Br J Obstet Gynaecol 2000;107:1392-1400.
19. Grady D, Gebretsadik T, Kerlikowski K, Ernster V, Petitti D: Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol 1995;85:304-315.
20. Bertone E, Weiderpass E: Low dose oestrogens and endometrial cancer. J Br Menopause Soc 2000;6:89-92.
21. Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson DL: Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 1986;67:326-330.
22. Lee RB, Burke TW, Park RC: Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncology 1990;36:189-191.
23. Chapman JA, DiSaia PJ, Osann K, Roth PD, Gillotte DL, Berman ML: Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 1996;175:1195-1200.
24. Suriano KA, McHale M, McLaren CE, Li KF, Re A, DiSaja PJ: Estrogen replacement therapy in endometrial cancer patients: A matched control study. Obstet Gynecol 2001;97:955-960.
25. Lauritzen C: Östrogensubstitution in der Postmenopause vor und nach behandeltem Genital- und Mammakarzinom; in Lauritzen C (ed): Menopause: Hormonsubstitution heute. Basel, Aesopus Verlag, 1993, pp. 76-80.
26. Bryant GW: Administration of estrogens in patients with a previous diagnosis of endometrial adenocarcinoma. South Med J 1990;83:725-726.
27. Baker DP: Estrogen-replacement therapy in patients with previous endometrial carcinoma. Compr Ther 1990;16:28-35.
28. Carr JA, Schoon PA, Look KY: An atypical recurrence of endometrial carcinoma following estrogen replacement therapy. Gynecol Oncol 1996;60:498-499.
29. Bullock JL, Massey FM, Gambrell RD Jr: Use of medroxyprogesterone acetate to prevent menopausal symptoms. Obstet Gynecol 1975;46:165-168.
30. Morrison JC, Martin DC, Blair RA, Anderson GD, Kincheloe BW, Bates GW, Hendrix JW, Rivlin ME, Forman EK, Propst MG, Needham R: The use of medroxyprogesterone acetate for relief of climacteric symptoms. Am J Obstet Gynecol 1980;138:99-104.
31. Albrecht BH, Schiff I, Tulchinsky D, Ryan KJ: Objective evidence that placebo and oral medroxyprogesterone acetate therapy diminish menopausal vasomotor flushes. Am J Obstet Gynecol 1981;139:631-635.
32. Schiff I, Tulchinsky D, Cramer D, Ryan KJ: Oral medroxyprogesterone in the treatment of postmenopausal symptoms. JAMA 1980;244:1443-1445.
33. Loprinzi CL, Michalek JC, Quella SK, O'Fallon JR, Hatfield AK, Nelimark RA, Dose AM, Fischer T, Johnson C, Klatt NE, et al: Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994;331:347-352.
34. Quella SK, Loprinzi CL, Sloan JA, Vaught NL, DeKrey WL, Fischer T, Finck G, Pierson N, Pisansky T: Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer 1998;82:1784-1788.
35. Farish E, Barnes JF, O'Donoghue F, Fletcher CD, Ekevall K, Hart DM: The role of megestrol acetate as an alternative to conventional hormone replacement therapy. Climacteric 2000;3:125-134.
36. Marsden J: Hormone replacement therapy and breast cancer. Lancet Oncol 2002;3:303-311.
37. Seeger H, Wallwiener D, Mueck AO: Comparison of the effect of progesterone, medroxyprogesterone acetate and norethisterone on the proliferation of human breast cancer cells. J Br Menopause Soc 2003;9:36-38.
38. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
39. Rossouw JE, Anderson GL, Prentice RL, La-Croix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
40. Mikkola TS, Clarkson TB: Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002;53:605-619.
41. Mueck AO, Seeger H, Haasis R, Gohlke-Bärwolf C, Schieber M, Schuchert A, Meinertz T: Effect of oral vs. transdermal estradiol on cGMP during exercise in women with coronary artery disease - randomized, double-blind, placebo-controlled crossover study. Circulation 1999;100(18 Suppl):1386.
42. Hillard T: Serving without stimulation. J Br Menopause Soc 2000;6(Suppl 2):11-13.
43. Mueck AO, Seeger H: Statins and menopausal health. J Br Menopause Soc 2002;8:141-146.
44. Kloosterboer HJ, Sands R: Intracinology: The secret of the tissue specificity of tibolone. J Br Menopause Soc 2000;6(Suppl 2):23-27.
45. Deutsche Gesellschaft für Senologie: Konsensus: Hormonsubstitution nach Mammakarzinom. Geburtshilfe Frauenheilkd 2002;62:1113-1115.
46. Mueck AO, Stoll KD: Opipramol bei menopausalem Syndrom als Alternative bei Kontraindikationen gegen Hormonsubstitution; in Müller WE, Möller HJ (eds): Opipramol, Sigmaligand und stimmungsaufhellendes Anxiolytikum. Neu-Isenburg, LinguaMed Verlag, 2001, pp 137-146.
47. Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K: Gabapentin's effects on hot flashes in postmenopausal women: A randomized controlled trial. Obstet Gynecol 2003;101:337-345.
48. Albertazzi P: Management of hot flushes without oestrogen. J Br Menopause Soc 2002;8:147-151.
49. Johnson EB, Muto MG, Yanushpolsky EH, Mutter GL: Phytoestrogen supplementation and endometrial cancer. Obstet Gynecol 2001;98(5 Pt 2):947-950.
50. North American Menopause Society: The role of isoflavones in menopausal health: Consensus opinion of the North American Menopause Society. Menopause 2000;7:215-229.
51. Glazier MG, Bowman MA: A review of the evidence for the use of phytoestrogens as a replacement for traditional estrogen replacement therapy. Arch Intern Med 2001;161:1161-1172.
52. Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, Mack TM: Estrogenprogestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997;89:1110-1116.
53. Persson I, Weiderpass E, Bergkvist L, Bergström R, Schairer C: Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 1999;10:253-260.
54. Beresford SA, Weiss NS, Voigt LF, McKnight B: Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997;349:458-461.